# 510(k) Summary

**Date:** 8 April 2008  
**Submitter:** Osypka Medical, Inc.  
7855 Ivanhoe Avenue, Suite 226, La Jolla, CA 92037  
**Contact Person:** Markus Osypka, Ph.D., President  
Osypka Medical, Inc.  
7855 Ivanhoe Avenue, Suite 226, La Jolla, California 92037  
**Phone:** (858) 454 0021  
**Fax:** (858) 454 0064

| Device Trade Names: | Cardiomatic™ | AESCULON®  
| | | CHF Clinic™  
| | | Hypertension Clinic™  
| | | Pacemaker Clinic™  
| OSYPKA MEDICAL® | AESCULON®  
| | CHF Clinic™  
| | Hypertension Clinic™  
| | Pacemaker Clinic™  

All of Version C2  

| Common / Usual Names: | Hemodynamic Monitor, Cardiac Output Monitor, Cardiovascular Monitor  
| Classification Names: | 21 CFR 870.2770 Impedance Plethysmograph  
| Regulatory Class: | Class II  
| Product Code: | DSB  
| Predicate Device: | K070895 AESCULON® Version C1.1

Osypka Medical, Inc.  
7855 Ivanhoe Avenue, Suite 226, La Jolla, CA 92037  
Phone (858) 454 0021  
Fax (858) 454 0064  
www.osypkamed.com
Device Description: The AESCULON® Version C2, including the models CHF Clinic™, Hypertension Clinic™ and Pacemaker Clinic™, is a noninvasive comprehensive cardiovascular monitor, also known as a hemodynamic monitor.

By application of an array of adhesive ECG type surface electrode to the body, the AESCULON® measures thoracic electrical bioimpedance (TEB) and in particular the changes of bioimpedance related to the cardiac cycle.

The AESCULON® determines hemodynamic parameters with respect to blood flow, vascular system (if the NIBP option is incorporated), contractility and fluid status.

Intended Use: The AESCULON®, AESCULON® CHF Clinic™, AESCULON® Hypertension Clinic™ and AESCULON® Pacemaker Clinic™ are intended for noninvasive continuous monitoring of hemodynamic parameters for adult, pediatric, and neonatal patients in hospitals, hospital-type facilities, mobile, and home environments.

Technology: The AESCULON® Version C2, including the models CHF Clinic™, Hypertension Clinic™ and Pacemaker Clinic™, is substantially equivalent to the predicate device AESCULON® Version C1.1 in terms of design, intended use and principal of operation. Measurement of thoracic electrical bioimpedance (TEB) and recording of the ECG is accomplished by attaching an array of ECG type surface electrodes to the patient. A high frequency, low amplitude patient auxiliary current is applied via the outer electrodes and the resulting voltage and the ECG is recorded between the inner electrodes.

For the estimation of stroke volume (SV) the AESCULON® Version C2 (new device) and Version C1.1 (predicate device) use the general relationship

\[ SV = V_{EPT} \cdot \bar{v}_{FT} \cdot FT \]

with \( V_{EPT} \) being the volume of electrically participating tissue, \( \bar{v}_{FT} \) being the mean blood velocity during flow time, and \( FT \) being the left ventricular flow time.
Both the AESCULON® Version C2 (new device) and Version C1.1 (predicate device) derive from the measurement of TEB:

- the base impedance $Z_0$,
- the magnitude of the maximum rate of change of impedance $\left| \frac{dZ(t)}{dt} \right|_{\text{MAX}}$, and
- the left-ventricular flow time $FT$.

### Theory / SV Algorithm

The AESCULON® Version C2 (new device) and Version C1.1 (predicate device) do not differ in the theoretical model applied to the measurement of the magnitude of the maximum rate of change of impedance $\left| \frac{dZ(t)}{dt} \right|_{\text{MAX}}$, which relates this magnitude to peak aortic blood acceleration. The AESCULON® Version C2 (new device) and Version C1.1 derive thereof an index of contractility (ICON™).

### Options

The AESCULON® Version C2 (new device) and Version C1.1 (predicate device) may incorporate a module and accessories for measurement of noninvasive blood pressure (NIBP) manufactured or supplied by SunTech Medical Instruments, Raleigh, NC (model ‘Advantage’).

The AESCULON® Version C2 (new device) and Version C1.1 (predicate device) may incorporate a module and accessories for pulse oximetry ($\text{SpO}_2$) manufactured or supplied by Masimo, Irvine, CA (Model ‘MS-11’).

### Summary Non-Clinical Testing

Demonstration of substantial equivalence between the AESCULON® Version C2 (new device) and the Version C1.1 (predicate device) was based on an assessment of non-clinical performance data.

### Summary Clinical Testing

Clinical testing not part of this submission.

### Conclusion

It is concluded that the AESCULON® Version C2 is as safe, as effective, and performs as well as the predicate device Version C1.1.
MAY 30, 2008

Osypka Medical, Inc.
c/o Mr. Markus Osypka, Ph.D.
President
7855 Ivanhoe Ave., Suite 226
La Jolla, CA 92037

Re: K081035
Aesculon®, Aesculon® CHF Clinic™, Aesculon® Hypertension Clinic and Aesculon® Pacemaker Clinic®
Regulation Number: 21 CFR 870.2770
Regulation Name: Impedance Plethysmograph
Regulatory Class: Class II (two)
Product Code: DSB
Dated: May 7, 2008
Received: May 12, 2008

Dear Dr. Osypka:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number: K081035

Device Name: AESCULON® Version C2
AESCULON® CHF Clinic™
AESCULON® Hypertension Clinic®
AESCULON® Pacemaker Clinic®

Indications for Use:

The AESCULON®, AESCULON® CHF Clinic™, AESCULON® Hypertension Clinic® and AESCULON® Pacemaker Clinic® are intended for noninvasive continuous monitoring of hemodynamic parameters for adult, pediatric, and neonatal patients in hospitals, hospital-type facilities, mobile, and home environments.

Prescription Use X AND / OR Over-The-Counter-Use
(Part 21 CFR 801 Subpart D) (Part 21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

[Signature]
(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K081035